头孢克洛缓释片与头孢氨苄缓释片治疗120例呼吸道感染的随机对照研究  

Cefaclor versus Cefalexin in the Treatment of 120 Cases of Bacterial Respiratory Infections: A Randomized Control Trial

作　　者：杜佳新[1] 顾玉红[2] 

机构地区：[1]哈尔滨医科大学附属第一医院,哈尔滨市150001 [2]哈尔滨医科大学附属肿瘤医院,哈尔滨市150081

出　　处：《中国医院用药评价与分析》2010年第7期642-644,共3页Evaluation and Analysis of Drug-use in Hospitals of China

摘　　要：目的:评价头孢克洛缓释片治疗细菌性呼吸道感染的疗效和安全性。方法:将120例呼吸道细菌性感染患者,随机分为两组。治疗组63例,采用头孢克洛缓释片口服;对照组57例,采用头孢氨苄缓释片口服,两组疗程均为7天。结果:头孢克洛缓释片治疗组的总有效率为90.4%,细菌学清除率为88.1%;头孢氨苄缓释片治疗组的总有效率为75.5%,细菌学清除率为80.0%。治疗过程中两组患者的不良反应均较轻微。结论:头孢克洛缓释片口服治疗呼吸道细菌性感染具有显著疗效。OBJECTIVE： To evaluate the efficacy and the safety of Cefaclor sustained release tablets for bacterial respiratory infections. METHODS： 120 patients with bacterial respiratory infections were randomly assigned to receive either Cefaclor sustained release tablets （ n = 63 ） or Cefalexin extended release tablets （ n = 57 ） for 7 days. RESULTS： The effective rate and bacterial clearance rate in Cefaclor sustained release tablets treated group were 90. 4% and 88. 1% ,respectively,as compared with 75. 5% and 80. 0% ,respectively in Cefalexin extended release tablets treated group. The side effects were mild in both groups. CONCLUSION： Cefaclor sustained release tablets have remarkable efficacy for bacterial respiratory infections.

关 键 词：头孢克洛缓释片 头孢氨苄缓释片 呼吸道感染 

分 类 号：R978.1[医药卫生—药品]